ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.59 -0.60%

-$0.13 today

Market cap
$3.04B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.45M

Average 1.66M

Big Five Numbers

ACADIA Pharmaceuticals Inc. growth analysis

Start with the long-run numbers that show whether ACAD compounds: return on capital and growth in sales, earnings, equity, and free cash flow.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/A+68.4%
Revenue
N/AN/A+27.5%+11.9%
Equity
N/AN/A+43.0%+63.9%
Cash
N/AN/A+15.7%-44.4%
ROIC
N/A-11.3%6.2%8.1%

Analysis

Latest growth is strongest in EPS at +68.4% and weakest in Cash at -44.4%. Three-year average ROIC is 6.2%, which helps show whether that growth is being earned efficiently.

Growth analysis

Is growth accelerating or fading?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+1.3% (5yr)5 analysts
RevenueN/AN/A+27.5%
+11.2% (5yr)12 analysts
Net IncomeN/AN/AN/A
+1.3% (5yr)12 analysts
EBITN/AN/AN/A
+38.2% (5yr)12 analysts

Analysis

Recent growth has been strongest in Revenue at +27.5% over three years. Forward estimates point to EBIT at +38.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Revenue segments

Where does the growth come from?

Break revenue down by product and geography to see which parts of the business drive the trend.

Revenue by segment

Where ACAD earns its revenue, as reported in company filings

  • Product
Revenue by segment for FY2018
Segment · FY2018 Revenue Share YoY
Product$223.81M100.0%—

Figures in USD.

Free cash flow

Does growth turn into cash?

Check whether reported growth converts into free cash flow after capital spending.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income$391.0M
+ D&A$11.8M
+ Stock-Based Comp$0
- Deferred Tax-$249.9M
- Working Capital-$89.8M
+ Other Non-Cash$46.7M
= Operating Cash Flow$109.8M
- Capex-$4.7M
= Free Cash Flow$105.1M

Analysis

FY2025 free cash flow is $105.1M. FCF conversion is 26.9% of net income. Operating cash flow was $109.8M, with capex of -$4.7M. The largest bridge item is Deferred Tax at -$249.9M.

Price targets

What do analysts expect from the price?

Compare the current price with the low, average, and high analyst targets.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for ACAD.

Sign in free

Analyst ratings

How do analysts rate the stock?

Review the buy, hold, and sell split and recent upgrades and downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for ACAD.

Sign in free

Competitor growth

How does ACADIA Pharmaceuticals Inc. grow against peers?

Compare historical and forecast growth with similar companies.

Competitor Growth

Peer CAGR comparison & forward estimates

CompanyMarket Cap10yr5yr3yrFwd

Praxis Precision Medicines, Inc.

PRAX

$9.17B———
—9 analysts

Axsome Therapeutics, Inc.

AXSM

$7.45B——+133.7%
+40.7% (5yr)8 analysts

LB Pharmaceuticals Inc Common Stock

LBRX

$1.39B———
—2 analysts

Rapport Therapeutics, Inc. Common Stock

RAPP

$1.25B———
—5 analysts

Alto Neuroscience, Inc.

ANRO

$1.18B———
—6 analysts

Contineum Therapeutics, Inc.

CTNM

$348.58M———
—2 analysts

MapLight Therapeutics, Inc.

MPLT

$308.98M———
—4 analysts

Vanda Pharmaceuticals Inc.

VNDA

$241.27M+7.0%-2.7%-5.3%
+17.8% (5yr)2 analysts

Anavex Life Sciences Corp.

AVXL

$86.53M———
—1 analysts

Neumora Therapeutics, Inc. Common Stock

NMRA

$80.59M———
—7 analysts

Questions

Growth questions

Common questions about ACAD's growth, answered from reported and forecast figures.

Is ACAD growing revenue?

Revenue grew 11.9% year over year, from $957.80M to $1.07B.

Is ACAD turning growth into profit?

The latest net margin is 36.5%, which shows how much revenue became net income.